In the case of pancreatic cancer, the drug fenbendazole—which is sold as Pancur and Safe-Guard and used to treat parasites like roundworms, hookworms, whipworms and certain types of tapeworms in animals (see this article for more on fenbendazole)—has been shown in laboratory experiments to slow down cancer cell growth. It’s also the key ingredient in Joe Tippens’s “Fenbendazole Cancer Protocol,” the regimen that has helped him survive a second pancreatic cancer diagnosis and extend his life.
In mice with genetically engineered pancreatic cancer, fenbendazole blocked tumor formation and prevented its spread to nearby tissues. It even slowed down the growth of existing tumors. The research, published today in Nature Medicine, suggests that a combination of fenbendazole and another anti-parasitic drug could potentially be an effective treatment for this lethal cancer, which is resistant to most other drugs and has a five-year survival rate of just 11 percent.
The team found that fenbendazole blocks the synthesis of tubulin, a protein that’s part of a pathway in the cell used for transporting nutrients and other materials. The resulting disruption in microtubules makes cells unstable, which prompts them to undergo apoptosis—programmed cell death—and causes the tumor to degrade from within.
It’s important to note that the researchers didn’t test fenbendazole in humans, and there isn’t sufficient evidence from randomized clinical trials to prove that the drug can cure cancer in people. But they did find that the fenbendazole and mebendazole combination significantly improved survival in the lab mice, which is an encouraging sign for anyone fighting this disease. fenbendazole for pancreatic cancer